ES2509741T3 - Proceso para preparar dihidropteridinonas y productos intermedios de las mismas - Google Patents

Proceso para preparar dihidropteridinonas y productos intermedios de las mismas Download PDF

Info

Publication number
ES2509741T3
ES2509741T3 ES11767449.9T ES11767449T ES2509741T3 ES 2509741 T3 ES2509741 T3 ES 2509741T3 ES 11767449 T ES11767449 T ES 11767449T ES 2509741 T3 ES2509741 T3 ES 2509741T3
Authority
ES
Spain
Prior art keywords
alkyl
compound
formula
intermediates
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11767449.9T
Other languages
English (en)
Spanish (es)
Inventor
Juergen Schnaubelt
Rolf Herter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43902841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2509741(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Application granted granted Critical
Publication of ES2509741T3 publication Critical patent/ES2509741T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D475/00Heterocyclic compounds containing pteridine ring systems
    • C07D475/06Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D475/00Heterocyclic compounds containing pteridine ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Hydrogenated Pyridines (AREA)
ES11767449.9T 2010-10-12 2011-10-11 Proceso para preparar dihidropteridinonas y productos intermedios de las mismas Active ES2509741T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10187194 2010-10-12
EP10187194 2010-10-12
PCT/EP2011/067696 WO2012049153A1 (en) 2010-10-12 2011-10-11 Process for manufacturing dihydropteridinones and intermediates thereof

Publications (1)

Publication Number Publication Date
ES2509741T3 true ES2509741T3 (es) 2014-10-17

Family

ID=43902841

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11767449.9T Active ES2509741T3 (es) 2010-10-12 2011-10-11 Proceso para preparar dihidropteridinonas y productos intermedios de las mismas

Country Status (18)

Country Link
US (1) US8546566B2 (cg-RX-API-DMAC7.html)
EP (1) EP2627656B1 (cg-RX-API-DMAC7.html)
JP (1) JP5937087B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140005877A (cg-RX-API-DMAC7.html)
CN (1) CN103168040A (cg-RX-API-DMAC7.html)
AU (1) AU2011315552B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013008883A2 (cg-RX-API-DMAC7.html)
CA (1) CA2813838A1 (cg-RX-API-DMAC7.html)
CL (1) CL2013000730A1 (cg-RX-API-DMAC7.html)
DK (1) DK2627656T3 (cg-RX-API-DMAC7.html)
EA (1) EA024256B1 (cg-RX-API-DMAC7.html)
ES (1) ES2509741T3 (cg-RX-API-DMAC7.html)
IL (1) IL224602A (cg-RX-API-DMAC7.html)
MX (1) MX2013003994A (cg-RX-API-DMAC7.html)
NZ (1) NZ606700A (cg-RX-API-DMAC7.html)
PH (1) PH12013500694A1 (cg-RX-API-DMAC7.html)
PL (1) PL2627656T3 (cg-RX-API-DMAC7.html)
WO (1) WO2012049153A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060035903A1 (en) * 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
JP2016525532A (ja) 2013-07-26 2016-08-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 骨髄異形成症候群の処置
CN104003989B (zh) * 2014-05-26 2015-11-11 苏州明锐医药科技有限公司 伏拉塞替及其中间体的制备方法
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
CN105646398B (zh) * 2014-12-05 2018-09-07 上海医药工业研究院 N-((1r,4r)-4-(4-(环丙基甲基)哌嗪-1-基)环己基)乙酰胺的制备方法
CN108610343A (zh) * 2018-06-12 2018-10-02 杨文思 一种用于治疗癌症的表皮生长因子受体抑制剂及其合成方法
BR112021011894A2 (pt) 2018-12-21 2021-09-08 Daiichi Sankyo Company, Limited Composição farmacêutica

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3537761A1 (de) 1985-10-24 1987-04-30 Bayer Ag Infusionsloesungen der 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7- (1-piperazinyl)-chinolin-3-carbonsaeure
JPH0276860A (ja) 1987-10-05 1990-03-16 Toyo Jozo Co Ltd 6−置換アルコキシ−2−オキソ−1,2−ジヒドロキノキサリン誘導体
FR2645152B1 (fr) 1989-03-30 1991-05-31 Lipha 3h-pteridinones-4, procedes de preparation et medicaments les contenant
US5043270A (en) 1989-03-31 1991-08-27 The Board Of Trustees Of The Leland Stanford Junior University Intronic overexpression vectors
US5198547A (en) 1992-03-16 1993-03-30 South Alabama Medical Science Foundation, Usa Process for N5-formylating tetrahydropteridines
TW274550B (cg-RX-API-DMAC7.html) 1992-09-26 1996-04-21 Hoechst Ag
EP1195372A1 (en) 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-heterocyclic substituted benzamide derivatives with antihypertensive activity
GB9418499D0 (en) 1994-09-14 1994-11-02 Ciba Geigy Ag Process for producing n-methylated organic pigments
CO4410190A1 (es) 1994-09-19 1997-01-09 Lilly Co Eli 3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
ES2154825T3 (es) 1995-05-19 2001-04-16 Novartis Ag Procedimiento para la hidrogenacion catalitica de nitro compuestos aromaticos.
US5698556A (en) 1995-06-07 1997-12-16 Chan; Carcy L. Methotrexate analogs and methods of using same
IL128956A0 (en) 1996-09-23 2000-02-17 Lilly Co Eli Olanzapine dihydrate D
PT1104420E (pt) 1998-08-11 2003-03-31 Pfizer Prod Inc 1-aril-3-arilmetil-1,8-naftiridin-4(1h)-onas
JP2003509425A (ja) 1999-09-15 2003-03-11 ワーナー−ランバート・カンパニー キナーゼ阻害剤としてのプテリジノン
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
CA2401368A1 (en) 2000-03-06 2001-09-27 Warner-Lambert Company 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
DE10018783A1 (de) 2000-04-15 2001-10-25 Fresenius Kabi De Gmbh Lagerstabile Infusionslösung des Ciprofloxacins mit verringertem Säuregehalt
US20020183292A1 (en) 2000-10-31 2002-12-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and corticosteroids
DE10058119A1 (de) 2000-11-22 2002-05-23 Bayer Ag Pepinotan-Kit
US6756374B2 (en) 2001-01-22 2004-06-29 Hoffmann-La Roche Inc. Diaminothiazoles having antiproliferative activity
US6960589B2 (en) 2001-03-09 2005-11-01 Abbott Laboratories Benzimidazoles that are useful in treating sexual dysfunction
WO2002076954A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
WO2002076985A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
JP4825375B2 (ja) 2001-08-28 2011-11-30 株式会社 資生堂 ジチアゾール化合物及びマトリックスメタロプロテアーゼ活性阻害剤、皮膚外用剤
US6806272B2 (en) 2001-09-04 2004-10-19 Boehringer Ingelheim Pharma Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
MXPA04002067A (es) 2001-09-04 2004-06-07 Boehringer Ingelheim Pharma Nuevas dihidropteridinonas, procedimientos para su preparacion y su uso como medicamento.
CA2469939C (en) 2001-12-14 2012-06-19 Applied Research Systems Ars Holding N.V. Method of inducing ovulation using a non-polypeptide camp level modulator
EP1501794A1 (de) 2002-05-03 2005-02-02 Schering Aktiengesellschaft Thiazolidinone und ihre verwendung als polo like kinase inhibitoren
FR2843114B1 (fr) 2002-08-01 2004-09-10 Poudres & Explosifs Ste Nale Procede de monomethylation d'heterocycles azotes
JP2006505522A (ja) 2002-08-08 2006-02-16 スミスクライン ビーチャム コーポレーション チオフェン化合物
US20040127504A1 (en) 2002-09-06 2004-07-01 Cowart Marlon D. Benzimidazoles that are useful in treating sexual dysfunction
GB2398565A (en) 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
DK1599478T3 (da) 2003-02-26 2007-09-17 Boehringer Ingelheim Pharma Dihydropteridinoner, fremgangsmåde til fremstilling af disse og anvendelse af disse som lægemiddel
US20070134200A1 (en) 2003-03-26 2007-06-14 Wyeth Immunogenic composition and methods
EP1617820B1 (en) 2003-04-14 2018-03-21 Vectura Limited Dry power inhaler devices and dry power formulations for enhancing dosing efficiency
CA2552540A1 (en) 2004-01-17 2005-07-28 Boehringer Ingelheim International Gmbh Use of substituted pteridines for the treatment of diseases of the respiratory tract
DE102004002557A1 (de) 2004-01-17 2005-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von substituierten Pyrimido(5,4-d)pyrimidinen zur Behandlung von Atemwegserkrankungen
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
DE102004034623A1 (de) 2004-07-16 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 6-Formyl-tetrahydropteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7759485B2 (en) * 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
EP1630163A1 (de) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1632493A1 (de) 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
CA2575804A1 (en) 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinones used as plk (polo like kinase) inhibitors
CA2578560A1 (en) 2004-08-27 2006-03-02 Boehringer Ingelheim International Gmbh Dihydropteridinones, method for the production thereof, and use thereof as a medicament
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
WO2007014838A1 (en) 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Dihydropteridinones in the treatment of respiratory diseases
EP2340837B1 (en) 2005-11-11 2017-03-15 Boehringer Ingelheim International GmbH Combination treatment of cancer comprising egfr/her2 inhibitors
US7439358B2 (en) * 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
US20090023733A1 (en) 2006-03-07 2009-01-22 Peter Cage Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them
NZ600394A (en) 2006-05-04 2014-04-30 Boehringer Ingelheim Int Polymorphs of a dpp-iv enzyme inhibitor
JP5261487B2 (ja) 2007-08-03 2013-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ジヒドロプテリジノン誘導体の結晶形
JP4642085B2 (ja) 2008-01-17 2011-03-02 日本下水道事業団 予測健全度を利用した施設管理および更新計画システム
EP2100894A1 (en) 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
US8025863B2 (en) * 2008-06-20 2011-09-27 Exxonmobil Research And Engineering Company Synthesis and use of MSE-framework type molecular sieves
WO2010025073A1 (en) * 2008-08-28 2010-03-04 Takeda Pharmaceutical Company Limited Dihydroimidazo [ 1, 5-f] pteridines as polo-like kinase inhibitors
ES2624622T3 (es) 2008-12-30 2017-07-17 Rigel Pharmaceuticals, Inc. Inhibidores de pirimidindiamina cinasa
EP2509592A1 (en) 2009-12-07 2012-10-17 Boehringer Ingelheim International GmbH Bibw 2992 for use in the treatment of triple negative breast cancer
JP5841548B2 (ja) 2010-02-17 2016-01-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ジヒドロプテリジノン、その製造方法及び使用
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US20130131069A1 (en) 2011-05-13 2013-05-23 Boehringer Ingelheim International Gmbh Method for treatment of solid malignancies including advanced or metastatic solid malignancies
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors

Also Published As

Publication number Publication date
JP2013539771A (ja) 2013-10-28
DK2627656T3 (da) 2014-09-08
AU2011315552B2 (en) 2015-05-21
JP5937087B2 (ja) 2016-06-22
MX2013003994A (es) 2013-06-05
AU2011315552A1 (en) 2013-02-21
EP2627656A1 (en) 2013-08-21
BR112013008883A2 (pt) 2017-10-10
WO2012049153A1 (en) 2012-04-19
KR20140005877A (ko) 2014-01-15
PH12013500694A1 (en) 2015-06-19
US8546566B2 (en) 2013-10-01
NZ606700A (en) 2015-06-26
EA201300443A1 (ru) 2013-11-29
CL2013000730A1 (es) 2013-08-09
CA2813838A1 (en) 2012-04-19
PL2627656T3 (pl) 2015-02-27
US20120238754A1 (en) 2012-09-20
CN103168040A (zh) 2013-06-19
IL224602A (en) 2016-04-21
EA024256B1 (ru) 2016-08-31
EP2627656B1 (en) 2014-08-20

Similar Documents

Publication Publication Date Title
ES2509741T3 (es) Proceso para preparar dihidropteridinonas y productos intermedios de las mismas
ES2498519T3 (es) Un procedimiento para la fabricación de SNAC (SALCAPROZATO SÓDICO)
ES2519446T3 (es) Proceso para la preparación de ácido 4-amino-butírico sustituido con biarilo o derivados del mismo y su uso en la producción de inhibidores de NEP
ES2486267T3 (es) 2-(Fenil 2-fluoro-substituido)-6-amino-5-cloro-4-pirimidinacarboxilatos y su uso como herbicidas
ES2495815T3 (es) Proceso para la síntesis de lacosamida
ES2548578T3 (es) Monosebacato de un derivado de pirazol
ES2663948T3 (es) Moduladores de TGR5 y método de uso de los mismos
ES2538366T3 (es) Procedimiento para la preparación de uretanos a partir de aminas aromáticas monofuncionales y difuncionales
RU2015145784A (ru) Способ получения циклоалкилкарбоксамидо-индольных соединений
CU24128B1 (es) Compuesto de benzoato conjugado a la hidrocodona (bz-hc)
AR076027A1 (es) Metodos e intermediarios para la preparacion de agentes farmaceuticos
PE20160090A1 (es) Metodos para sintetizar un analogo de la prostaciclina
MY165061A (en) Method and system for helping to position a component on a structural element
RU2013147638A (ru) Новое соединение сложного эфира карбоновой кислоты и способ его получения, и композиция душистых веществ
ES2527191T3 (es) Procedimiento e intermedios para la preparación de un ingrediente activo
IN2014CN04421A (cg-RX-API-DMAC7.html)
ES2541857T3 (es) Procesos para preparar ciclopropilamidas e intermedios asociados con estas
TW201129550A (en) Method for producing diepoxy compound
ES2496447T3 (es) Procedimiento de preparación de un aminoácido a partir de 2-aminobutirolactona
EA201071001A1 (ru) Способ получения комбретастатина
MX2009011574A (es) Metodos para la preparacion de derivados de n-isobutil-n-(2-hidrox i-3-amino-4-fenilbutil)-p-nitrobencensulfonilamida.
MX2019000138A (es) Procesos novedosos para preparacion de estimuladores de guanilato ciclasa soluble.
RU2008105019A (ru) N-замещенные 4-метил-2,6-дихлорникотиноил-мочевины в качестве антидотов 2,4-д на подсолнечнике
EA201390183A1 (ru) Способ получения соединения osi-906
RU2016118315A (ru) Способ получения вигетана и применение вигетана в качестве средства, увеличивающего статическую и динамическую работоспособность